Anti-Candida albicans effect of the protein-carbohydrate fraction obtained from the coelomic fluid of earthworm Dendrobaena veneta.
Animals
Antifungal Agents
/ isolation & purification
Apoptosis
/ drug effects
Candida albicans
/ drug effects
Candidiasis
/ drug therapy
Cell Wall
/ drug effects
Cytotoxins
/ isolation & purification
Drug Evaluation, Preclinical
Fibroblasts
Humans
Microbial Sensitivity Tests
Oligochaeta
/ chemistry
Primary Cell Culture
Skin
/ cytology
Toxicity Tests
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
07
2018
accepted:
11
02
2019
entrez:
12
3
2019
pubmed:
12
3
2019
medline:
28
11
2019
Statut:
epublish
Résumé
An antifungal active fraction (AAF) from the coelomic fluid (CF) of the earthworm Dendrobaena veneta was isolated. The aim of the study was to analyze the antifungal activity of the AAF and to carry out chemical characterization of the fraction. The active fraction showed antifungal activity against a clinical C. albicans isolate, C. albicans ATCC 10231, and C. krusei ATCC 6258. It effectively reduced the metabolic activity of C. albicans cells and influenced their morphology after 48 hours of incubation. Scanning electron microscopy (SEM) images revealed loss of integrity of the cell wall induced by the active fraction. Calcofluor White staining showed changes in the structure of the C. albicans cell wall induced by the AAF. The fungal cells died via apoptosis and necrosis after the treatment with the studied fraction. Electrophoresis under native conditions revealed the presence of two compounds in the AAF, while SDS/PAGE gel electrophoresis showed several protein and carbohydrate compounds. The active fraction was analyzed using Raman spectroscopy, MALDI TOF/TOF, and ESI LC-MS. The Raman analysis confirmed the presence of proteins and determined their secondary structure. The MALDI TOF/TOF analysis facilitated detection of four main compounds with a mass of 7694.9 m/z, 12292.3 m/z, 21628.3 m/z, and 42923.2 m/z in the analyzed fraction. The presence of carbohydrate compounds in the preparation was confirmed by nuclear magnetic resonance (NMR) and gas chromatography (GC-MS). The ATR-FTIR spectrum of the AAF exhibited high similarity to the spectrum of egg white lysozyme. The AAF showed no endotoxicity and cytotoxicity towards normal skin fibroblasts (HSF); therefore, it can be used for the treatment of skin and mucous membrane candidiasis in the future. Given its efficient and selective action, the fraction seems to be a promising preparation with antifungal activity against C. albicans.
Identifiants
pubmed: 30856188
doi: 10.1371/journal.pone.0212869
pii: PONE-D-18-22477
pmc: PMC6411149
doi:
Substances chimiques
Antifungal Agents
0
Cytotoxins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0212869Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Med Microbiol. 2013 Jan;62(Pt 1):10-24
pubmed: 23180477
J Biol Chem. 1994 Feb 18;269(7):5059-63
pubmed: 8106483
Biochim Biophys Acta. 2014 Oct;1840(10):3115-22
pubmed: 25018005
Acta Biochim Biophys Sin (Shanghai). 2004 Apr;36(4):297-302
pubmed: 15253156
Front Immunol. 2017 Jun 07;8:629
pubmed: 28638380
Pharm Biol. 2011 Mar;49(3):269-75
pubmed: 21323479
J Microbiol. 2011 Apr;49(2):171-7
pubmed: 21538235
Mol Med Rep. 2017 Mar;15(3):1135-1142
pubmed: 28138698
Arch Pathol Lab Med. 1984 Aug;108(8):616-8
pubmed: 6204621
Structure. 2012 Sep 5;20(9):1498-507
pubmed: 22819216
J Proteome Res. 2017 Aug 4;16(8):3053-3067
pubmed: 28658951
Nature. 1970 Aug 15;227(5259):680-5
pubmed: 5432063
Nature. 1962 Jul 21;195:281-3
pubmed: 14491328
J Mater Sci Mater Med. 2011 Jul;22(7):1653-61
pubmed: 21626309
J Cell Biol. 1993 Dec;123(6 Pt 2):1821-33
pubmed: 8276900
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
Biopolymers. 2012 Jun;97(6):322-36
pubmed: 21882171
J Appl Microbiol. 2012 Nov;113(5):1106-19
pubmed: 22816366
J Invertebr Pathol. 2012 Jan;109(1):83-90
pubmed: 22019387
Q Rev Biophys. 2017 Jan;50:e9
pubmed: 29233221
J Biomed Opt. 2012 Jan;17(1):017007
pubmed: 22352673
Anal Biochem. 2000 Jan 15;277(2):167-76
pubmed: 10625503
Anal Biochem. 1982 Jan 1;119(1):115-9
pubmed: 6176137
Sci Rep. 2016 Jun 17;6:28106
pubmed: 27312998
Biotechnol Lett. 2003 Aug;25(16):1317-23
pubmed: 14514059
Biometals. 2001 Mar;14(1):85-94
pubmed: 11368280
Methods Enzymol. 2005;405:50-65
pubmed: 16413310
J Mol Biol. 2005 May 6;348(3):671-85
pubmed: 15826663
PLoS One. 2017 Jan 18;12(1):e0170041
pubmed: 28099525
Pathog Dis. 2013 Jun 21;69(1):46-61
pubmed: 23794449
Biochim Biophys Acta. 1998 Oct 22;1408(1):67-76
pubmed: 9784609
Nat Protoc. 2006;1(6):2856-60
pubmed: 17406544
Comp Biochem Physiol C Toxicol Pharmacol. 2001 Mar;128(3):401-11
pubmed: 11255113
Sci Rep. 2016 Mar 01;6:22475
pubmed: 26926993
Biophys J. 2007 Apr 15;92(8):2885-95
pubmed: 17277183
Acta Crystallogr D Biol Crystallogr. 2009 Jan;65(Pt 1):49-57
pubmed: 19153466
Mycopathol Mycol Appl. 1969 May 28;37(4):320-30
pubmed: 5797620
Peptides. 2011 Jun;32(6):1146-50
pubmed: 21539875
Biochim Biophys Acta. 1952 Mar;8(3):302-9
pubmed: 14934741